I have not seen it. I do not believe that it is necessarily drug or patient specific. I have had a number of patients who have developed the syndrome after stopping imatinib, have subsequently gone on to dasatinib after relapsing and then stopped dasatinib, all on the TRAD discontinuation study and none of them have had recurrent symptoms.
But as Tim says, we still do not know a lot about the syndrome

It is an interesting question. I have never seen this type of syndrome in a patient who switched to another TKI, but it could be confused with the initial toxicity features of the next TKI, I guess. I think it is very likely to be a TKI-wide effect, but we are still learning about the withdrawal syndrome. It would be interesting to hear from other clinicians about this issue.


ORIGINAL CASE:
I had a question from a patient who had the musculoskeletal pain syndrome when I stopped imatinib for a trial of TFR. It was quite severe and they really don’t want to go through this again. However unfortunately I had to restart imatinib for a rising Bcr-Abl after which the pain syndrome ceased but replaced by a few chronic side effects from imatinib (cramp, GIT disturbance, oedema) and I have suggested changing to a 2nd generation drug. However they are very worried about getting the imatinib withdrawal syndrome again and wanted to know if it happens if one changes from imatinib to an alternative. I can’t recall any reports of this happening but do you know if there syndrome is only a problem with cessation of a TKI or could it be drug specific and might still occur if changing from imatinib to a 2nd generation TKI?

I had a question from a patient who had the musculoskeletal pain syndrome when I stopped imatinib for a trial of TFR. It was quite severe and they really don’t want to go through this again. However unfortunately I had to restart imatinib for a rising Bcr-Abl after which the pain syndrome ceased but replaced by a few chronic side effects from imatinib (cramp, GIT disturbance, oedema) and I have suggested changing to a 2nd generation drug. However they are very worried about getting the imatinib withdrawal syndrome again and wanted to know if it happens if one changes from imatinib to an alternative. I can’t recall any reports of this happening but do you know if there syndrome is only a problem with cessation of a TKI or could it be drug specific and might still occur if changing from imatinib to a 2nd generation TKI?